All News #Library
Biotech
Tang Returns As Aurinia CEO With $50M Offer After Kezar Buyout
30 Mar 2026 //
BIOSPACE
Tang takes over Aurinia after FDA brouhaha—Chutes & Ladders
27 Mar 2026 //
FIERCE BIOTECH
Aurinia reports positive Phase 1 results for AUR200
30 Jun 2025 //
BUSINESSWIRE
Aurinia to Share AUR200 Ph1 Study Results on June 30, 2025
29 Jun 2025 //
BUSINESSWIRE
Aurinia Reports Q3 Results & Restructuring for LUPKYNIS Growth
07 Nov 2024 //
BUSINESSWIRE
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a
20 Jun 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
02 May 2023 //
BUSINESSWIRE
Aurinia Announces Topline Data from Renal Biopsy Sub-study of the AURORA Trial
05 Apr 2023 //
BUSINESSWIRE

Market Place
Sourcing Support